Show simple item record

dc.contributor.authorJones, Tanya
dc.contributor.authorVan Breda, Karin
dc.contributor.authorCharles, Bruce
dc.contributor.authorDean, Angela J
dc.contributor.authorMcDermott, Brett M
dc.contributor.authorNorris, Ross
dc.date.accessioned2017-05-03T13:48:05Z
dc.date.available2017-05-03T13:48:05Z
dc.date.issued2009
dc.date.modified2010-08-13T07:24:03Z
dc.identifier.issn0269-3879
dc.identifier.doi10.1002/bmc.1204
dc.identifier.urihttp://hdl.handle.net/10072/30219
dc.description.abstractA simple, rapid, selective, accurate and precise method is described for the determination of risperidone and its active metabolite, 9-hydroxyrisperidone, in plasma using a chemical derivative of risperidone (methyl-risperidone) as the internal standard. The sample workup involved a single-step extraction of 1 mL plasma, buffered to pH 10, with heptane-isoamyl alcohol (98:2 v/v), then evaporation of the heptane phase and reconstitution of the residue in mobile phase. HPLC separation was carried out at on C18 column using a mobile phase of 0.05 m dipotassium hydrogen orthophosphate (containing 0.3% v/v triethylamine) adjusted to pH 3.7 with orthophosphoric acid (700 mL), and acetonitrile (300 mL). Flow rate was 0.6 mL/min and the detection wavelength was 280 nm. Retention times were 2.6, 3.7 and 5.8 min for 9-hydroxy risperidone, risperidone and the internal standard, respectively. Linearity in spiked plasma was demonstrated from 2 to 100 ng/mL for both risperidone and 9-hydroxyrisperidone (r = 0.999). Total imprecision was less than 13% (determined as co-efficient of variation) and the inaccuracy was less than 12% at spiked concentrations of 5 and 80 ng/mL. The limit of detection, determined as three times the baseline noise, was 1.5 ng/mL. Clinical application of the assay was demonstrated for analysis of post-dose (0.55-4.0 mg/day) samples from 28 paediatric patients (aged 6.9-17.9 years) who were taking risperidone orally for behavioural and emotional disorders.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherJohn Wiley & Sons Ltd.
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom929
dc.relation.ispartofpageto934
dc.relation.ispartofissue9
dc.relation.ispartofjournalBiomedical Chromatography
dc.relation.ispartofvolume23
dc.rights.retentionY
dc.subject.fieldofresearchAnalytical chemistry
dc.subject.fieldofresearchAnalytical chemistry not elsewhere classified
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchcode3401
dc.subject.fieldofresearchcode340199
dc.subject.fieldofresearchcode3214
dc.titleDetermination of risperidone and 9-Hydroxyrisperidone using HPLC, in plasma of children and adolescents with emotional and behavioural disorders
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Pharmacy
gro.date.issued2009
gro.hasfulltextNo Full Text
gro.griffith.authorJones, Tanya


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record